Selio Medical Limited appears in FDA device records as the applicant for the Pre-B Seal Lung Biopsy Plug System, classified as an absorbable lung biopsy plug under regulation number 878.4755 and product code OMT. The supplied collection holds one linked 510(k) record, K263664, decided 3 November 2026 as substantially equivalent; the record sample is that same single entry, so the collection and the sample describe the same filing. A separate earlier clearance, K243722, is documented in the numbered sources and covers additional model configurations. Company descriptions of the technology come from Selio's own website and from a European Commission project record. [1][2][8]
The applicant and its documented device
FDA records name Selio Medical Limited as the applicant for the Pre-B Seal Lung Biopsy Plug System, Model FG0004, under K263664. The filing lists product code OMT, regulation number 878.4755, device class 2, and a decision of substantially equivalent dated 3 November 2026, with the application received 5 October 2026. The same record gives the applicant address as Unit 53 Guinness Enterprise Centre, Taylors Lane, Dublin 8, Ireland, and names Colm McGarvey as contact. That is a filing address in the FDA record, not a verified headquarters designation. [1]
Selio's own website describes the company as a biomaterial medical device company based in the Guinness Enterprise Centre in Dublin, founded through BioInnovate Ireland and Trinity College Dublin. It states that Selio developed a patented platform biomaterial technology for minimally invasive access and interventional procedures, and that its first product, the Pre. B Seal Lung Biopsy Plug System, is FDA cleared for use in lung biopsy procedures to reduce pneumothorax. These are company statements attributed to their publisher. [2]
Two dated 510(k) clearances
K243722 was received 3 December 2024 and decided 8 April 2025 as substantially equivalent, according to the FDA premarket notification record. The same record lists the device classification name as Absorbable Lung Biopsy Plug, product code OMT, regulation 878.4755, review panel Anesthesiology, and a traditional review not conducted by a third party. The FDA clearance letter for K243722 is dated 19 May 2025 and names the Pre-B Seal Lung Biopsy Plug System in 15cm (FG0001) and 16cm (FG0002) models, among others. [3][4]
K263664 is the later filing in the supplied collection, received 5 October 2026 and decided 3 November 2026 as substantially equivalent, with clearance type listed as Special and a summary provided. Its device name is the Pre-B Seal Lung Biopsy Plug System, Model FG0004. The two filings together document a model family spanning FG0001, FG0002 and FG0004; the sources do not state how many clearances the company holds in total. [1][3]
Device components and deployment
The K243722 clearance letter describes a delivery system attached to a prefilled hydrogel syringe, with the device purged before being advanced into the lung under CT imaging for deployment of the hydrogel plug. The same letter references markings and a depth marker ball. This is the most specific component description in the numbered sources; the sources do not provide clinical outcome data for the device. [4]
The FDA openFDA fields attached to K263664 list the device name as Absorbable Lung Biopsy Plug and the medical specialty description as General, Plastic Surgery, while the review advisory committee is recorded as Anesthesiology. The Total Product Life Cycle database entry for Selio Medical Limited shows one substantially equivalent decision for the manufacturer. That count reflects the database view at its stated update date, not a measure of sales, total portfolio or safety performance. [1][7]
Publicly funded development
A European Commission CORDIS record describes a project titled for development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsy, under grant agreement 190103391, funded by the European Innovation Council. The project ran from 1 October 2022 to 30 September 2024 and is marked closed. The record describes the device as a gateway technology intended to make biopsy a safer procedure and open biopsy to more patients. [8]
Ownership, parent company, customers and commercial availability are not established by the numbered sources. Selio's website mentions support from Trinity College Dublin, which is a stated affiliation rather than a verified corporate parent. No recall records appear in the supplied collection. [2]
